Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images
暂无分享,去创建一个
Yann Cointepas | Pierre Payoux | Georges El Fakhri | Aurélie Kas | Marie-Odile Habert | Zoulikha Malek | Philippe Chaumet-Riffaud | Emmanuel Itti | Philippe Remy | Y. Cointepas | P. Remy | P. Payoux | G. El Fakhri | M. Habert | P. Chaumet‐Riffaud | A. Kas | E. Itti | Z. Malek
[1] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.
[2] N. Alpert,et al. Comparison of 4 methods for quantification of dopamine transporters by SPECT with [123I]IACFT. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] V. Dhawan,et al. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: A PET study , 2002, Synapse.
[4] R. Felix,et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients , 2005, Journal of Neural Transmission.
[5] Vesna Sossi,et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.
[6] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[7] J. C. Stoof,et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] Jan Booij,et al. Iodine-123-N-ω-Fluoropropyl-2β-Carbomethoxy-3β-(4-Iodophenyl)Tropane SPECT in Healthy Controls and Early-Stage, Drug-Naive Parkinson's Disease , 1998 .
[9] Karl J. Friston,et al. Rapid Assessment of Regional Cerebral Metabolic Abnormalities in Single Subjects with Quantitative and Nonquantitative [18F]FDG PET: A Clinical Validation of Statistical Parametric Mapping , 1999, NeuroImage.
[10] Karl J. Friston,et al. Statistical parametric maps in functional imaging: A general linear approach , 1994 .
[11] Marc Laruelle,et al. Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions , 1994 .
[12] M. Kaufman,et al. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's‐diseased striatum , 1991, Synapse.
[13] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[14] P. Remy,et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD) , 1999, Movement disorders : official journal of the Movement Disorder Society.
[15] M Laruelle,et al. Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. , 1994, Journal of neurochemistry.
[16] Ralph Myers,et al. Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.
[17] O. Pogarell,et al. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years , 2001, Nuclear medicine communications.
[18] J D Speelman,et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] Akinori Nakamura,et al. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies , 2004, NeuroImage.
[20] J. Seibyl,et al. Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.
[21] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[22] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[23] André Aurengo,et al. Scatter and cross-talk corrections in simultaneous Tc-99m/I-123 brain SPECT using constrained factor analysis and artificial neural networks , 2000 .
[24] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[25] D J Wyper,et al. Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.
[26] S J Kish,et al. [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.
[27] J. Booij,et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease , 2001, Journal of Neural Transmission.
[28] D. Altman,et al. Statistics Notes: Measurement error and correlation coefficients , 1996, BMJ.
[29] K. Ishii,et al. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] J. Ashburner,et al. Nonlinear spatial normalization using basis functions , 1999, Human brain mapping.
[31] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[32] V J Cunningham,et al. 11C-Diprenorphine Binding in Huntington's Disease: A Comparison of Region of Interest Analysis with Statistical Parametric Mapping , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] Chris Rorden,et al. Spatial Normalization of Brain Images with Focal Lesions Using Cost Function Masking , 2001, NeuroImage.
[34] P B Hoffer,et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] P. Seeman,et al. The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus , 1991, Journal of neurochemistry.
[36] Karl J. Friston,et al. Statistical parametric mapping , 2013 .
[37] Manuel Desco,et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans , 2003, NeuroImage.